PD-L1 Antibody (DA196)
PD-L1 Antibody (DA196)
Recombinant monoclonal mouse antibody
Description
Programmed Death Ligand 1 (PD-L1), also known as CD274 and B7-H1, is a transmembrane protein expressed on the surface of resting T-cells. Binding to its receptor PD-1, a T-cell immune checkpoint, T-cell activation is inhibited and autoimmune reaction is stopped. Some tumor cells use this mechanism to prevent apoptosis and obtain resistance against CD8+ T-cell mediated cell lysis. PD-L1 (QR001) is suitable to detect sentinel lymph node melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC) as well as triple-negative breast cancer(TNBC). 1-16
References
1. Butte MJ, Pena-Cruz V et al. (2008). Mol Immunol. 45(13): 3567-72.
2. Ostrand-Rosenberg S, Horn LA, Haile ST (2014). J Immunol. 193 (8): 3835-41.
3. Freeman GJ, Long AJ et al. (2000). J Exp Med. 192(7): 1027-34.
4. Sharpe AH, Wherry EJ et al. (2007). Nat Immunol. 8(3): 239-45.
5. Patel SP, Kurzrock R (2015). Mol Cancer Ther. 14(4): 847-56.
6. Büttner R, Gosney JR et al. (2017). J Clin Oncol. 35(34): 3867-76.
7. Scheel AH, Baenfer G et al. (2017). Histopathology. doi: 10.1111/his.13375.
8. Ghorani E, Kaur B et al. (2017). Lancet. 390: 2343-45. Supplementary appendix.
9. Hofman P (2017). Expert Rev Mol Diagn. 17(12): 1097-1108.
10. Menguy S, Prochazkova-Carlotti M et al. (2018). Am J Surg Pathol. 42(3): 326-34.
11. 2017. Der Pathologe. 4: 345-50
12. Jöhrens K, Büttner R et al. QuIP Ring Trial Q1/2017.
13. Lantuejoul S, Damotte D et al. (2019). J Thorac Dis. 11(Suppl 1): 89-101.
14. Lantuejoul S, Adam J et al. (2018). Ann Pathol. 38(2): 110-25.
15. Scimeca M, Bonfiglio R et al. (2019). Urol Oncol. pii: S1078-1439(19)30068-7.
16. Bianchi A, Annibali O et al. (2019).
2. Ostrand-Rosenberg S, Horn LA, Haile ST (2014). J Immunol. 193 (8): 3835-41.
3. Freeman GJ, Long AJ et al. (2000). J Exp Med. 192(7): 1027-34.
4. Sharpe AH, Wherry EJ et al. (2007). Nat Immunol. 8(3): 239-45.
5. Patel SP, Kurzrock R (2015). Mol Cancer Ther. 14(4): 847-56.
6. Büttner R, Gosney JR et al. (2017). J Clin Oncol. 35(34): 3867-76.
7. Scheel AH, Baenfer G et al. (2017). Histopathology. doi: 10.1111/his.13375.
8. Ghorani E, Kaur B et al. (2017). Lancet. 390: 2343-45. Supplementary appendix.
9. Hofman P (2017). Expert Rev Mol Diagn. 17(12): 1097-1108.
10. Menguy S, Prochazkova-Carlotti M et al. (2018). Am J Surg Pathol. 42(3): 326-34.
11. 2017. Der Pathologe. 4: 345-50
12. Jöhrens K, Büttner R et al. QuIP Ring Trial Q1/2017.
13. Lantuejoul S, Damotte D et al. (2019). J Thorac Dis. 11(Suppl 1): 89-101.
14. Lantuejoul S, Adam J et al. (2018). Ann Pathol. 38(2): 110-25.
15. Scimeca M, Bonfiglio R et al. (2019). Urol Oncol. pii: S1078-1439(19)30068-7.
16. Bianchi A, Annibali O et al. (2019).
Specifications
Application:
IHC (FFPE)
Host:
Mouse
Subclass:
IgG1/κ
Immunogen:
Synthetic peptide from human PD-L1
Cellular location:
Cell membrane
Control:
Placenta
Order information
| DMRD0244 | Concentrate | IVD(R) |
| DMRD0244 | 10 ml Ready to use | IVD(R) |
| DMRD0244 | 6 ml Ready to use | IVD(R) |
| DMRD0244 | 3 ml Ready to use | IVD(R) |
